Chester County News and Community Website
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) unveiled new clinical data suggesting its investigational therapy buntanetap may reverse cognitive decline in Parkinson’s disease patients who also exhibit Alzheimer’s-related amyloid …
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) unveiled compelling new data from its Phase 2 study of VP-315, a first-in-class oncolytic peptide immunotherapy, showing strong local immune activation …
New Cancer Data Hints at a Surgery-Free Future — Verrica’s VP-315 Shows Big Promise Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that all 84 clinical sites in its pivotal Phase 3 study for early Alzheimer’s disease (AD) are now fully activated and …
Annovis Bio Reaches Key Milestone as Alzheimer’s Phase 3 Trial Gains Momentum Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) reported third-quarter 2025 financial results and outlined continued progress across its expanding immuno-inflammatory pipeline, emphasizing execution in both oral kinase inhibitors and …
Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026 Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the development of QTORIN™ pitavastatin, a novel investigational therapy for disseminated superficial actinic porokeratosis (DSAP), a rare and progressive skin disease …
Palvella Unveils New Therapy Targeting Rare Premalignant Skin Disease DSAP Read More
EXTON, PA — Lungpacer Medical announced the enrollment of the first six patients in its landmark STARI (STimulation to Activate RespIration) clinical trial, a study evaluating the company’s next-generation AeroNova …
Lungpacer Launches Pivotal STARI Trial to Transform Critical Care Recovery Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced new clinical findings indicating that its lead candidate, buntanetap, reduces inflammation and improves cellular health in patients with Alzheimer’s disease, suggesting …
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients Read More
CHESTERBROOK, PA — Neuraptive Therapeutics, Inc. announced the enrollment of the first patient in its phase 3 clinical trial evaluating NTX-001, an investigational therapy designed to improve outcomes in patients …
Neuraptive Therapeutics Enrolls First Patient in Phase 3 Trial for NTX-001 Nerve Repair Therapy Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it will expand development of its investigational therapy QTORIN™ 3.9% rapamycin anhydrous gel into clinically significant angiokeratomas, a rare and debilitating …
Palvella Expands QTORIN Rapamycin Program Into Rare Angiokeratomas Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the publication of a peer-reviewed article in Biomolecules detailing the pharmacokinetic profile of a newly developed crystal form of buntanetap, its …
Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug Read More